Related Experiment Videos
Postnatal thyroxine administration for idiopathic respiratory distress syndrome in preterm infants
M Amato1, S Pasquier, A Carasso
1Department of Perinatal Medicine, University Clinic of Obstetrics and Gynecology, Berne, Switzerland.
Insights
Postnatal thyroxine (T4) administration did not improve outcomes for preterm infants with idiopathic respiratory distress syndrome (IRDS). This study found no significant benefits in mortality, ventilation duration, or bronchopulmonary dysplasia development.
Area of Science:
- Neonatal Medicine
- Pediatric Endocrinology
- Respiratory Medicine
Background:
- Idiopathic respiratory distress syndrome (IRDS) is a common respiratory complication in preterm infants.
- Thyroxine (T4) plays a crucial role in fetal and neonatal development, including lung maturation.
- The potential benefit of postnatal T4 supplementation in preterm infants with IRDS requires investigation.
Purpose of the Study:
- To evaluate the effect of intravenous thyroxine (T4) administration on the clinical course of idiopathic respiratory distress syndrome (IRDS) in preterm infants.
- To compare outcomes between preterm infants with IRDS treated with T4 and a control group.
Main Methods:
- A study involving 36 preterm infants (gestation < 34 weeks) diagnosed with IRDS.
- Eighteen infants received intravenous thyroxine (T4) treatment, while 18 served as a control group.
- Key outcomes assessed included mortality rate, duration of mechanical ventilation, need for high oxygen environment, and development of bronchopulmonary dysplasia.
Main Results:
- Postnatal T4 treatment resulted in serum T4 levels comparable to healthy term infants.
- No statistically significant differences were observed between the T4-treated and control groups regarding mortality rate (p > 0.3).
- The duration of mechanical ventilation (p > 0.3), need for high oxygen environment (p > 0.05), and development of bronchopulmonary dysplasia (p > 0.2) showed no significant variations between groups.
Conclusions:
- Postnatal administration of thyroxine (T4) does not offer significant clinical benefits for preterm infants suffering from idiopathic respiratory distress syndrome (IRDS).
- Current evidence suggests T4 supplementation is not an effective therapeutic strategy for improving major respiratory outcomes in this vulnerable population.
Abstract:
Thirty-six preterm infants of less than 34 weeks of gestation with idiopathic respiratory distress syndrome (IRDS) were studied. Eighteen of them were treated with intravenous thyroxine (T4) and compared with 18 control prematures to evaluate the effect of postnatal T4 administration on the course of IRDS. After treatment, serum T4 levels were similar to those of healthy term infants. No statistically significant effect on mortality rate, duration of mechanical ventilation (p greater than 0.3), need of high oxygen environment (p greater than 0.05) and development of bronchopulmonary dysplasia (p greater than 0.2) was observed between the two groups. These observations show that postnatal use of T4 does not carry any benefit for preterm infants with IRDS.